Clinical strategy in oncology: rethink animal studies
Oncology is shifting fast. Base your clinical strategy on predictive cell testing, not animal studies. Identify the right tumors early and avoid dead ends.
juillet 30, 2025
MEDExpansion
Strategic advisory for oncology start-ups
External CMO with 30 + years’ experience, bringing strategic vision to de-risk and accelerate the roadmap from preclinical to clinical PoC
Flexible CMO support
Acting as your CMO, strategic and operational, tailored to your needs
Sequential analysis methodology
To focus resources on tumors with the highest potential for PoC and rule out early costly clinical dead ends
Let’s Talk
F: +41 79 624 79 55
M: a.rinaldi@medexpansion.ch
The Sequential Analysis Method
My structured sequential analysis bridges cell-stage results and tomorrow’s clinical reality :
Advanced cell-test insights
Seq2TraqTM matrix filter
More targeted animal studies
De-risked phase
2 trial
Faster clinical
PoC
CMO, clinician‑oncologist turned pharma leader with a startup mindset
- A Swiss‑French oncologist and clinical‑strategy leader, Dr Alain Rinaldi brings more than 30 years of end‑to‑end oncology‑drug‑development experience, from patient care to global pharma leadership, and biotech entrepreneurship.
- In 2014 he founded MedExpansion to guide early‑stage oncology start‑ups from advanced cell stage to phase 2 PoC, acting as their flexible, fractional CMO.
- Beyond his advisory work, he co‑founded Ibex Therapeutics, an oncology supportive-care startup (https://ibextx.ch), and serves as its CMO, keeping first‑hand startup realities at the centre of his guidance.
- These combined roles empower him to craft vision‑driven, de‑risked
0
+
Years Experienced
0
+
Start-up interactions
Insights & Updates
News & Article
Welcome to my Clinical Dev Blog, a repository for my LinkedIn posts, 1‑minute videos and slide carousels.
Here I share cutting-edge, experience‑based insights on oncology clinical development, practical ideas to help you de‑risk projects, speed up trials and reach phase 2 PoC faster
Biotome and immunotherapy: a new predictive biomarker?
The biotome may impact response to immunotherapy. Could it become a new predictive biomarker in oncology? A look at recent scientific insights.
juillet 28, 2025
Rethinking phase 2 trials: beyond animal models
FDA’s exemption challenges phase 2 design in oncology. Should we move away from animal models and focus on early, cell-level clinical analysis?
juillet 25, 2025
FDA has eased preclinical requirements
Good news for animal welfare: the FDA has eased preclinical requirements
juillet 17, 2025
